重组人p53腺病毒注射液联合放射治疗对人淋巴瘤细胞的抑制作用  

Inhibitory effect of recombinant adenovirus encoding human p53 tumor suppressor gene (rAd-p53) combined with radiation therapy on human lymphoma cells lines growth

作　　者：俞泽阳[1] 范我[2] 吴锦昌[3] 李栋庆[2] 朱然[2] 万建美[2] 王永青[2] 

机构地区：[1]苏州大学第二附属医院,苏州215004 [2]苏州大学放射医学与公共卫生学院,苏州215123 [3]南京医科大学附属苏州市立医院,苏州215001

出　　处：《辐射研究与辐射工艺学报》2008年第3期183-188,共6页Journal of Radiation Research and Radiation Processing

基　　金：国家自然科学基金(30471974)资助

摘　　要：本研究利用四氮唑盐(Methyl thiazolyl tetrazolium,MTT)比色法、激光共聚焦型显微镜扫描技术和流式细胞术分析重组人p53腺病毒注射液(商品名今又生,rAd-p53注射液)对人淋巴瘤细胞的抑制作用及其辐射增敏性。结果表明,rAd-p53对淋巴瘤细胞的抑制作用呈时间和剂量依赖性效应,但其抑制效应不明显均未达到有效抑制率。放疗及联合治疗后,细胞抑制率及凋亡率明显增高,形态和周期均发生变化,但两者直接差别不显著。以上说明rAd-p53对人淋巴瘤细胞的转染率还有待进一步提高,以增强细胞对辐照的敏感性。In this paper investigating inhibitory effect and radiation sensitization of recombinant adenovirus encoding human p53 tumor suppressor gene （rAd-p53） on human lymphoma cell lines has been performed by MTT, Laser confocal scanning microscope （LCSM） and flow cytometry. The results show that the inhibitory effect of rAd-p53 on human lymphoma cell lines is not obvious enough even though it is both dose-dependent and time-dependent. It has been found that cell inhibition and apoptosis ratios increases and cell cycle and morphology features changes apparently in radiation therapy and combined therapy. But there is no obvious difference in them. The results indicate that the transfection ratio of rAd-p53 on human lymphoma cell lines needs much improvement in order to strengthen the sensitivity of cell to radiation.

关 键 词：基因治疗 RAD-P53 放射治疗 人淋巴瘤细胞 

分 类 号：R811.5[医药卫生—放射医学] R730.5[医药卫生—临床医学]